Dietary Nut and Legume Intake and Risk of Crohn's Disease and Ulcerative Colitis

被引:0
作者
Lopes, Emily W. [1 ,2 ]
Yu, Zeling [1 ]
Walsh, Shawna E. [3 ]
Casey, Kevin [2 ]
Ananthakrishnan, Ashwin N. [1 ,2 ]
Richter, James M. [1 ]
Burke, Kristin E. [1 ,2 ]
Chan, Andrew T. [1 ,2 ,4 ]
Khalili, Hamed [1 ,2 ,4 ,5 ]
机构
[1] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA USA
[3] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA USA
[4] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
[5] Broad Inst & Harvard, Cambridge, MA USA
基金
美国国家卫生研究院;
关键词
Crohn's disease; ulcerative colitis; inflammatory bowel disease; nutrition; body mass index; MEDITERRANEAN DIET; GUT MICROBIOME; HEART-DISEASE; CONSUMPTION; ASSOCIATIONS; VALIDITY; ADULTS;
D O I
10.1093/ibd/izaf032
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: We investigated the relationship between nut and legume intake and risk of Crohn's disease (CD) and ulcerative colitis (UC). Methods: We conducted a prospective cohort study of 223 283 adults from the Nurses' Health Study (NHS), NHSII, and Health Professionals Follow-Up Study (1986-2017), excluding those with inflammatory bowel disease (IBD) at baseline. Food frequency questionnaires were used to calculate nut and legume intake. Inflammatory bowel disease was self-reported on questionnaires and confirmed via blinded record review. Using Cox proportional hazards models, we calculated adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for CD and UC according to categories of nut and legume intake. Results: In over 5 460 315 person-years of follow-up (CD = 371, UC = 481), neither nut nor legume intake was associated with CD or UC risk. Compared to those who never consumed nuts, those who consumed nuts >= 2 times/week had an aHR = 0.96 (95% CI, 0.63-1.47; P-trend = 0.57) for CD and 1.30 (95% CI, 0.92-1.84; P-trend = 0.36) for UC. Compared to those who consumed legumes 0-3 times/month, those who consumed legumes >= 4 times/week had an aHR of 1.26 (95% CI, 0.78-2.04; P-trend = 0.59) for CD and 0.72 (95% CI, 0.44-1.18; P-trend = 0.20) for UC. Baseline BMI modified the relationship between nut intake and CD risk (P-int = 0.03). In those with BMI >= 25, the aHR for CD was 0.14 (95% CI, 0.03-0.56; P = .006) per additional serving/day of nuts compared with 0.88 (95% CI, 0.45-1.74; P = .72) for those with BMI <25. Conclusions: Nut and legume intake were not associated with CD or UC risk. However, higher nut intake decreased CD risk in overweight or obese individuals. Thus, personalized-risk stratification, rather than generalized dietary recommendations, may be important for IBD prevention strategies. Lay Summary Here, we show that overall nut and legume intake was not associated with risk for development of IBD; however, higher nut intake decreased Crohn's disease risk in those with elevated body mass index.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Abatacept for Crohn's Disease and Ulcerative Colitis
    Sandborn, William J.
    Colombel, Jean-Frederic
    Sands, Bruce E.
    Rutgeerts, Paul
    Targan, Stephan R.
    Panaccione, Remo
    Bressler, Brian
    Geboes, Karl
    Schreiber, Stefan
    Aranda, Richard
    Gujrathi, Sheila
    Luo, Allison
    Peng, Yun
    Salter-Cid, Luisa
    Hanauer, Stephen B.
    [J]. GASTROENTEROLOGY, 2012, 143 (01) : 62 - U575
  • [32] Colitis in a patient with familial Mediterranean fever: Is it Crohn's disease or ulcerative colitis?
    Hoshi, Ayano
    Shimodate, Yuichi
    Gotoda, Tatsuhiro
    Takezawa, Rio
    Nishimura, Naoyuki
    Mouri, Hirokazu
    Matsueda, Kazuhiro
    Mizuno, Motowo
    Matsumoto, Takayuki
    [J]. DEN OPEN, 2025, 5 (01):
  • [33] Metaproteomics of fecal samples of Crohn's disease and Ulcerative Colitis
    Lehmann, T.
    Schallert, K.
    Vilchez-Vargas, R.
    Benndorf, D.
    Puettker, S.
    Sydor, S.
    Schulz, C.
    Bechmann, L.
    Canbay, A.
    Heidrich, B.
    Reichl, U.
    Link, A.
    Heyer, R.
    [J]. JOURNAL OF PROTEOMICS, 2019, 201 : 93 - 103
  • [34] Current position on Vedolizumab for ulcerative colitis and Crohn's disease
    Schreiber, S.
    Dignass, A. U.
    Hartmann, H.
    Kruis, W.
    Rogler, G.
    Siegmund, B.
    Stallmach, A.
    Witte, C.
    Bokemeyer, B.
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (06): : 591 - 602
  • [35] A comparison of diverticulitis in Crohn's disease versus ulcerative colitis
    Persaud, Alana
    Ahmed, Ahmed
    Kakked, Gaurav
    Shulik, Oleg
    Ahlawat, Sushil
    [J]. JGH OPEN, 2019, 3 (06): : 508 - 512
  • [36] Clinical Features of Ulcerative Colitis and Crohn's Disease in Turkey
    Ozin, Yasemin
    Kilic, Mesut Zeki Yalin
    Nadir, Isilay
    Cakal, Basak
    Disibeyaz, Selcuk
    Arhan, Mehmet
    Dagli, Ulku
    Tunc, Bilge
    Ulker, Aysel
    Sahin, Burhan
    [J]. JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2009, 18 (02) : 157 - 162
  • [37] New biologic therapeutics for ulcerative colitis and Crohn's disease
    Mozaffari, Shilan
    Nikfar, Shekoufeh
    Abdolghaffari, Amir Hossein
    Abdollahi, Mohammad
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (05) : 583 - 600
  • [38] Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis
    Eduardo Garcia Vilela
    Henrique Osvaldo da Gama Torres
    Fabiana Paiva Martins
    Maria de Lourdes de Abreu Ferrari
    Marcella Menezes Andrade
    Aloísio Sales da Cunha
    [J]. World Journal of Gastroenterology, 2012, 18 (09) : 872 - 881
  • [39] Optimizing Biologic Agents in Ulcerative Colitis and Crohn’s Disease
    O’Toole A.
    Moss A.C.
    [J]. Current Gastroenterology Reports, 2015, 17 (8)
  • [40] Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis
    Hagan, Matilda
    Cross, Raymond K.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2015, 14 (09) : 1473 - 1479